Abstract: The present invention relates to an anti-SARS-CoV-2 S protein-specific antibody or an antigen-binding fragment thereof, and therapeutic and diagnostic uses thereof. The anti-SARS-CoV-2 S protein-specific antibody or antigen-binding fragment thereof according to the present invention can bind specifically to the S protein, which plays an important role in the infiltration of SARS-CoV-2 into host cells, to inhibit the infection of SARS-CoV-2, and thus can be advantageously used as a therapeutic agent for COVID-19 and as a diagnostic agent and diagnostic kit for COVID-19.

Abstract: The present disclosure relates to an antibody or an antigen-binding fragment thereof specifically binding to GRP94, and uses thereof. A GRP94 antibody or antigen-binding fragment thereof according to the present disclosure has very high specificity and affinity to GRP94, and excellent growth-inhibiting, infiltration-inhibiting, and angiogenesis-inhibiting effects on colorectal cancer cell lines, and thus can be useful as a composition for treating cancer, inhibiting cancer metastasis, and inhibiting angiogenesis.

Abstract: The present disclosure relates to a deglycosylated antibody binding specifically to C-type lectin domain family 14, member A (clec14a). More particularly, the present disclosure relates to a deglycosylated antibody that comprises a light chain variable region comprising CDR1 having a certain sequence and binds specifically to clec14, and use thereof, for example, a pharmaceutical composition containing the antibody for preventing or treating an angiogenesis-related disease.

Abstract: A method for treating a VCAM-1 mediated disease comprising administering a therapeutically effective amount of a monoclonal antibody to a patient in need thereof. The monoclonal antibody specifically binds to both human and mouse vascular cell adhesion molecule-1 (VCAM-1). The monoclonal antibody comprises(a) a light chain CDR 1 region defined by SEQ ID NO:5, a light chain CDR 2 region defined by SEQ ID NO:6, and a light chain CDR 3 region defined by SEQ ID NO:7, and (b) a heavy chain CDR 1 region defined by SEQ ID NO:8, a heavy chain CDR 2 region defined by SEQ ID NO:.9 or 11, and a heavy chain CDR 3 region defined by SEQ ID NO:10 or 12.

Abstract: The present invention relates to a monoclonal antibody that specifically binds to vascular cell adhesion molecule-1 (VCAM-1 or CD106). Specifically, the present invention relates to an antibody that specifically binds to both human and mouse vascular cell adhesion molecule-1 (VCAM-1), a method for producing the same, a composition for diagnosis or treatment comprising them and a method for diagnosis or treatment using them. The monoclonal antibody of the present invention is the first recombinant monoclonal antibodies that is specific to human and mouse VCAM-1. In addition, the monoclonal antibody of the present invention shows a strong affinity to VCAM-1 expressed in rat skeletal muscle and porcine endothelial cells as well as human and mouse endothelial cells and is found to strongly inhibit the interaction between leukocytes and activated endothelial cells.

Abstract: The present invention relates to a monoclonal antibody that specifically binds to vascular cell adhesion molecule-1 (VCAM-1 or CD106). Specifically, the present invention relates to an antibody that specifically binds to both human and mouse vascular cell adhesion molecule-1 (VCAM-1), a method for producing the same, a composition for diagnosis or treatment comprising them and a method for diagnosis or treatment using them. The monoclonal antibody of the present invention is the first recombinant monoclonal antibodies that is specific to human and mouse VCAM-1. In addition, the monoclonal antibody of the present invention shows a strong affinity to VCAM-1 expressed in rat skeletal muscle and porcine endothelial cells as well as human and mouse endothelial cells and is found to strongly inhibit the interaction between leukocytes and activated endothelial cells.

Abstract: The present invention provides peptide complexes comprising phospholipase D and one or morephospholipase D-interacting peptides. The peptide complexes are useful in screening assays foridentifying compounds effective in modulating the peptide complexes and in treating and/or preventing diseases associated with phospholipase D and it's interacting partners. In addition, methods for screening modulators of the peptide complexes or interacting members thereof are provided.